(Total Views: 196)
Posted On: 02/20/2019 10:26:08 AM
Post# of 46498
$BSGM Santa Monica, CA, Feb. 20, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company successfully conducted first patient cases using PURE EP(tm) System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
The patient studies were conducted by Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.
“With the use of the PURE EP(tm) System I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP(tm) System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes,” commented Dr. Natale. BioSig Announces Successful First-In-Human Use of PURE EP System https://finance.yahoo.com/news/biosig-announc...00889.html
The patient studies were conducted by Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.
“With the use of the PURE EP(tm) System I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP(tm) System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes,” commented Dr. Natale. BioSig Announces Successful First-In-Human Use of PURE EP System https://finance.yahoo.com/news/biosig-announc...00889.html
(0)
(0)Scroll down for more posts ▼
